SCHEMBL21725543

SCHEMBL21725543

CC(C)c1ccc(N(C)C)nc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NCF1 P14598 1/20 0.35
CRHR1 P34998 1/20 0.33
GAA P10253 1/20 0.33
NOTUM Q6P988 1/20 0.32
MDM2 Q00987 1/20 0.31
MCHR1 Q99705 1/20 0.31
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
ITGB2 P05107 1/20 0.30
ICAM1 P05362 1/20 0.30
ITGAL P20701 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21859736 0.83 CRHR1 (0.38) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL21725545 0.81 CRHR1 (0.37) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL22193256 0.81 AR (0.38) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL23717810 0.76 CYP3A4 (0.37) CYP3A4TSHRNOTUMPDE3BPDE3A
SCHEMBL12871319 0.76 NOTUM (0.34) CYP3A4TSHRHSD17B10NOTUMPDE3B
SCHEMBL26137557 0.76 CYP3A4 (0.37) CYP3A4TSHRNOTUMPDE3BPDE3A
SCHEMBL22193255 0.76 NCF1 (0.38) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL25332545 0.74 CYP1A2 (0.37) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL24918576 0.74 XPO1 (0.37) NOTUMPDE3BPDE3A
SCHEMBL10138886 0.74 BACE1 (0.37) GAANOTUMMCHR1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R AR 413/4885CYP1A2 1383/4885CYP3A4 2798/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R AR 413/4885CYP1A2 1383/4885CYP3A4 2798/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R AR 413/4885CYP1A2 1383/4885CYP3A4 2798/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R AR 413/4885CYP1A2 1383/4885CYP3A4 2798/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R AR 413/4885CYP1A2 1383/4885CYP3A4 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.